The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

Impact · against what's priced in

The primary catalyst is the upcoming August pricing disclosure for Eli Lilly's oral GLP-1, which will determine if revenue guides are conservative or if pricing erosion is accelerating. Meanwhile, the sector's recovery depends on the stability of U.S. trade import caps and Medicare negotiations, with Merck and AbbVie facing the highest downside risk if these policy carve-outs are reversed.

LLY+0.30

No priced-in read yet